Loss of CYLD might be associated with development of salivary gland tumors

Oncology Reports

Volumn 19, Issue 6, 2008, Pages 1421-1427

  Fukuda, Masakatsu ^a   Hiroi, Miki ^a   Suzuki, Seiji ^a   Ohmori, Yoshihiro ^a   Sakashita, Hideaki ^a  

^a MEIKAI UNIVERSITY SCHOOL OF DENTISTRY   (Japan)

Author keywords

Adenoid cystic carcinomas; Cylindromatosis gene; I B kinase ; I B kinase ; Inhibitory B ; Nuclear factor KB

Indexed keywords

CYLINDROMATOSIS PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CYLD PROTEIN, HUMAN; I KAPPA B KINASE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; RNA INTERFERENCE; SALIVARY GLAND TUMOR; TRANSCRIPTION REGULATION; TUMOR CELL CULTURE; TUMOR SUPPRESSOR GENE; ADENOID CYSTIC CARCINOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ADENOID CYSTIC; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; I-KAPPA B KINASE; MALE; MIDDLE AGED; NF-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SALIVARY GLAND NEOPLASMS; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEINS;

EID: 48849108196     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Lever W and Schaumburg-Lever G: Histopathology of the skin. 7th edition. Lippincott, JB, Philadelphia, pp848-851, 1990.
2. Tellechea O, Reis JP, Ilheu O and Baptista AP: Dermal cylindroma. An immunohistochemical study of thirteen cases. Am J Dermatopathol 17: 260-265, 1995.
3. Biggs PJ, Wooster R, Ford D, et al: Familial cylindromatosis (turban tumour syndrome) gene localised to chromosome 16q12-q13: evidence for its role as a tumour suppressor gene. Nat Genet 11: 441-443, 1995.
4. Biggs PJ, Chapman P, Lakhani SR, Bum J and Stratton MR: The cylindromatosis gene (cyld1) on chromosome 16q may be the only tumour suppressor gene involved in the development of cylindromas. Oncogene 12: 1375-1377, 1996.
5. Bignell GR, Warren W, Seat S, et al: Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 25: 160-165, 2000.
6. Takahashi M, Rapley E, Biggs PJ, et al: Linkage and LOH studies in 19 cylindromatosis families show no evidence of genetic heterogeneity and refine the CYLD locus on chromosome 16q12-q13. Hum Genet 106:58-65, 2000.
7. Brummelkamp TR, Nijman SM, Dirac AM and Bernards R: Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 424: 797-801, 2003.
8. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D and Courtois G: The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424: 801-805, 2003.
9. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A and Mosialos G: CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424: 793-796, 2003.
10. Li Q and Verma IM: NF-kappaB regulation in the immune system. Nat Rev Inummol 2: 725-734, 2002.
11. Karin M, Cao Y, Greten FR and Li ZW: NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2: 301-310, 2002.
12. Orlowski RZ and Baldwin AS Jr: NF-kappaB as a therapeutic target in cancer. Trends Mot Med 8: 385-389, 2002.
13. Baeuerle PA and Baltimore D: I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 242: 540-546, 1988.
14. Baeuerle PA and Baltimore D: A 65-kappaD subunit of active NF-kappaB is required for inhibition of NF-kappaB by I kappaB. Genes Dev 3: 1699-1698, 1999.
15. Haskill S, Beg AA, Tompkins SM, et al: Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity. Cell 65: 1281-1289, 1991.
16. Karin M: The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J Biol Chem 274: 27339-27342, 1999.
17. Mercurio F, Zhu H, Murray BW, et al: IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science 278: 860-866, 1997.
18. May MJ and Ghosh S: IkappaB kinases: kinsmen with different crafts. Science 284: 271-273, 1999.
19. Karin M: How NF-κB is activated: the role of the 10 kinase (IKK) complex. Oncogene 18: 6867-6874, 1999.
20. Smahi A, Courtois G, Rabia SH, et al: The NF-kappaB signalling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes. Hum Mol Genet 11: 2371-2375, 2002.
21. Fukuda M, Fukuda F, Horiuchi Y, Oku Y, Suzuki S, Kusama K and Sakashita H: Expression of CYLD, NF-kappaB and NF-kappaB-related factors in salivary gland tumors. In Vivo 20: 467-472, 2006.
22. Shirasuna K, Sato M and Miyazaki T: A neoplastic epithelial duct cell line established from an irradiated human salivary gland. Cancer 48: 745-752, 1981.
23. Ohmori Y and Hamilton TA: Interleukin-4/STAT6 represses STAT1 and NF-kappa B-dependent transcription through distinct mechanisms. J Biol Chem 275: 38095-38103, 2000.
24. Seifert G (ed): Histological typing of salivary gland tumours. 2nd edition. World Health Organization International Histological Classification of Tumors, Springer-Verlag, Berlin, pp21-47, 1991.
25. Sobin LH and Wittekind CH (eds): UICC TNM classification of malignant tumors. 5th edition. John Wiley and Sons, Inc., New York, pp20-24, 2002.
26. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr and Sledge GW Jr: Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17: 3629-3639, 1997.
27. Nakayama H, Ikebe T, Beppu M and Shirasuna K: High expression levels of nuclear factor κB, IκB kinase α and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer 92: 3037-3044, 2001.
28. Rani MR, Asthagiri AR, Singh A, et al: A role for NF-κB in the induction of ß-R1 by interferon-ß. J Biol Chem 276: 44365-44368, 2001.
29. Dajee M, Lazarov M, Zhang JY, et al: NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 421: 639-643, 2003.
30. Deng J, Miller SA, Wang HY, et al: ß-catenin interacts with and inhibits NF-κB in human colon and breast cancer. Cancer Cell 2: 323-334, 2002.
31. Huang TT and Miyamoto S: Post-repression activation of NF-κB requires the amino-terminal nuclear export signal specific to IκBα. Mol Cell Biol 21: 4737-4747, 2001.
32. Li Q, Estepa G, Memet S, Israel A and Verina IM: Complete lack of NF-kappaB activity in IKK1 and IKK2 double-deficient mice: additional defect in neurulation. Genes Dev 14: 1729-1733, 2000.
33. Li Q, Lu Q, Hwang JY, Buscher D, Lee KF, Izpisua-Belmonte JC and Verma IM: KK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev 13: 1322-1328, 1999.
34. Sizemore N, Lerner N, Dombrowski N, Sakurai H and Stark GR: Distinct roles of the IκB kinase α and β subunits in liberating nuclear factor κB (NF-κB) from IκB and in phosphorylating the p65 subunit of NF-κB. J Biol Chem 277: 3863-3869, 2001.